Showing 15 posts of 18 posts found.


Powerful new data for MSD’s bladder cancer drug stops trial early

November 16, 2016
Research and Development MSD, pembrolizumab

MSD has released new data which reinforces the efficacy of its anti-PD-1 therapy pembrolizumab in patients with advanced urothelial (bladder) …


OncoMed initiates Phase Ib immuno-oncology combination clinical trial

March 18, 2016
Medical Communications, Research and Development Merck, OncoMed, clinical trial, demcizumab, immuno-oncology, immuno-oncology combination, pembrolizumab, phase ib

OncoMed (NASDAQ: OMED) has announced the beginning of its Phase Ib clinical trial to investigate if the combination of demcizumab …

Keytruda image

BioLineRx to test lead candidate with MSD’s Keytruda in pancreatic cancer

January 13, 2016
Research and Development MSD, immunotherapy, keytruda, pembrolizumab

Israeli biopharma company BioLineRx has announced a collaboration with MSD on a Phase II study investigating its lead oncology candidate, …

Keytruda image

MSD’s Keytruda impresses in lung cancer chemotherapy trial

December 21, 2015
Manufacturing and Production, Research and Development MSD, PD-L1, docetaxel, keytruda, lung cancer, non small cell lung cancer, non-small cell lung cancer, pd-1, pembrolizumab

MSD’s Keytruda significantly improved overall survival (OS) compared to chemotherapy in people with lung cancer and PD-L1 expression, a trial …

Keytruda image

MSD’s Keytruda shows promise in multiple myeloma

December 7, 2015
Manufacturing and Production MSD, Revlimid, dexamethasone, keytruda, multiple myeloma, pembrolizumab

MSD has announced that it has initiated two Phase III studies based in part on the strength of early data, …

Merck image

Sales up at MSD while Keytruda hits survival target in late-stage trial

October 28, 2015
Research and Development, Sales and Marketing MSD, Merck, financial results, keytruda, pembrolizumab

Worldwide sales at MSD were $10.1 billion in the third quarter of 2015, a 4% increase after accounting for the …


MSD’s Keytruda receives green light from NICE for NHS use

October 12, 2015
Sales and Marketing MSD, Merck, NICE, keytruda, melanoma, pembrolizumab, skin cancer

The UK healthcare watchdog NICE has recommended Keytruda as a treatment for advanced skin cancer – its second endorsement of …

Advanced melanoma

Novartis and Merck skin cancer drugs move through pipeline

August 20, 2015
Manufacturing and Production, Research and Development, Sales and Marketing Merck, Novartis, Odomzo, basal cell carcinoma, keytruda, melanoma, pembrolizumab, skin cancer, sonidegib

Both Novartis and Merck have hit regulatory milestones with their skin cancer drugs in the EU and the US. Novartis’ …

Merck image

Merck to test Keytruda combinations

May 8, 2015
Sales and Marketing BMS, Daiichi Sankyo, Merck, Plexxikon, keytruda, pembrolizumab

Merck will be teaming up with Daiichi Sankyo’s subsidiary Plexxikon to investigate immunotherapy combinations in cancer. A collaborative clinical trial …


EMA approves BMS’ Opdivo for advanced skin cancer

April 27, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Merck, Yervoy, ipilimumab, keytruda, melanoma, nivolumab, opdivo, pembrolizumab, skin cancer

Bristol-Myers Squibb has earned a recommendation from the EMA for its cancer immunotherapy treatment Opdivo as a monotherapy for patients …

Merck image

Merck seeks new Keytruda indication in US

April 20, 2015
Sales and Marketing Cancer, FDA, NSCLC, PD-L1, US, keytruda, lung, pembrolizumab

Merck is seeking FDA approval for its successful melanoma drug Keytruda to be used treating lung cancer. The Supplemental Biologics …

Merck image

Merck lines up early-stage Keytruda combo trial

April 1, 2015
Research and Development, Sales and Marketing Cancer, Merck, entinostat, keytruda, pd1, pembrolizumab, syndax

Merck is planning for Keytruda’s future by launching early-stage trials of the drug in combination with an investigational treatment from …

Keytruda image

Merck’s Keytruda trial stopped early after beating BMS’ Yervoy on survival

March 25, 2015
Research and Development, Sales and Marketing BMS, Merck, Yervoy, ipilimumab, keytruda, pembrolizumab

A trial comparing two potential blockbuster cancer treatments has been stopped early, after Merck’s Keytruda beat BMS’ Yervoy in a …

Keytruda image

Merck’s cancer drug sees first ever early access nod

March 11, 2015
Sales and Marketing Cancer, ICR, Merck, eams, early access, keytruda, melanoma, oncology, pembrolizumab

Merck’s skin cancer drug Keytruda has become the first drug to be approved through the new Early Access to Medicines …

Merck image

Merck acquires Swiss firm OncoEthix

December 19, 2014
Sales and Marketing Cancer, FDA, Merck, OTX015, cubist, keytruda, oncoethix, pembrolizumab

Hot on the heals of its Cubist buyout Merck has confirmed the acquisition of OncoEthix, a Swiss based firm which …

Latest content